Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine

David M. Ficker, M. Privitera, G. Krauss, A. Kanner, J. L. Moore, T. Glauser

Research output: Contribution to journalArticle

51 Scopus citations

Abstract

The authors conducted a 3-month, prospective, open-label study assessing the effects of switching from immediate-release carbamazepine formulations to an equal total daily dose of carbamazepine extended-release capsules (CBZ-ERC) in adolescents and adults with epilepsy. Using validated, epilepsy-specific measures the authors found that switching to CBZ-ERC significantly improved patients' adverse events and quality-of-life measures. Switching to CBZ-ERC also improved seizure control.

Original languageEnglish (US)
Pages (from-to)593-595
Number of pages3
JournalNeurology
Volume65
Issue number4
DOIs
StatePublished - Aug 23 2005
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine'. Together they form a unique fingerprint.

  • Cite this